ArticleJournal of radiation research2026
Effects of combination metformin and nintedanib therapy in a mouse model of irradiation-induced pulmonary fibrosis.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Radiation-induced lung injury, a well-recognized complication of thoracic radiotherapy, can progress to pulmonary fibrosis, sharing pathological features with idiopathic pulmonary fibrosis. Although nintedanib is widely used as an antifibrotic agent, the therapeutic benefit of combination strategies remains partially understood. Therefore, in this study, we aimed to evaluate the effects of combined metformin and nintedanib treatment in a mouse model of irradiation-induced lung fibrosis. Female C57BL/6 mice were subjected to localized irradiation of 90 Gy in the left lung and treated daily with metformin, nintedanib or both drugs for 6 weeks. Lung fibrosis was assessed using gross examination, hydroxyproline quantification, histopathological scoring and quantitative image analysis. Changes in fibrosis- and injury-related proteins were examined by western blotting, including transforming growth factor-β (TGF-β), a profibrotic cytokine; SMAD family member 7 (SMAD7), an inhibitory regulator of TGF-β signaling; and surfactant protein D (SP-D), a lung epithelial injury-associated protein. Nintedanib-containing treatments improved histological lung injury in irradiated mice, including reduced collagen deposition, low pathological scores and preserved air space structure. Hydroxyproline content was also lower in the combination treatment group than in the other groups. The nintedanib-containing treatments suppressed irradiation-induced upregulation of transforming growth factor-β expression, and SMAD7 expression was selectively upregulated following combined treatment. In addition, elevated SP-D level following irradiation was partially reduced following nintedanib administration. These findings suggest that combined metformin and nintedanib treatment may provide a broader protective profile against radiation-induced pulmonary fibrosis, particularly in association with SMAD7 upregulation, although further studies are required to clarify whether the combination provides significant advantages over nintedanib monotherapy.
Indexed as
Identifiers
42502979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.